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Abstract
Background: This meta-analysis aimed to evaluate the efficacy of carotid endarterectomy (CE) compared with
carotid angioplasty (CA) in preventing stroke. Whether the use of CE is more efficient in preventing stroke than
CA is a matter of debate.
Methods: Data were gathered from randomized controlled trials to evaluate the effect of CE compared with CA on
the risk of stroke. Electronic searches in PubMed, Embase, and the Cochrane Library were performed to identify
studies till November 2014. Only randomized controlled trials performed on patients who received either CE or CA
for stroke prevention were included.
Results: Nine relevant trials (n = 7163) that met the inclusion criteria were identified. In a pooled analysis, CE
resulted in 35 % reduction in relative risk (RR) for short-term stroke [RR, 0.65; 95 % confidence interval (CI):
0.47–0.89; P = 0.007)] and 22 % reduction in RR for long-term stroke (RR, 0.78; 95 % CI: 0.66–0.93; P = 0.006)
relative to CA. However, CE also increased the risk of 30-day myocardial infarction by 114 % compared with CA
(RR, 2.14; 95 % CI: 1.30–3.53; P = 0.003). Sensitivity analyses suggested that CE might influence the risk of 30-day
major vascular events and 1-year major vascular events compared with CA.
Conclusions: CE could reduce the risk of stroke (whether short term or long term), but resulted in a relative
increase in the risk of myocardial infarction. This study might guide appropriate judgments about treatment
approach. It also provided evidence to justify general guidelines for patients with carotid artery stenosis.
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Background
Cerebrovascular disease, either ischemic or hemorrhagic
stroke, is the leading cause of premature mortality and
morbidity worldwide for both men and women [1–3].
Asian countries have a higher incidence of stroke com-
pared with Western countries [4]. Over the past few
years, many studies have shown a strong correlation be-
tween carotid artery stenosis and stroke [5, 6]. It has
been suggested that carotid artery stenosis should be
corrected as a therapeutic approach to prevent stroke
events. However, the use of carotid endarterectomy (CE)
compared with carotid angioplasty (CA) for preventing
stroke has not been shown consistently to be beneficial.
CE was recommended as the standard therapy, which
could reduce the risk of stroke in patients with carotid
artery stenosis [7]. However, in many cases, a high residual
risk of stroke persists after CE. Hence, it is necessary to
explore additional effective preventive therapies [8]. Re-
cently, endovascular treatments [9] (CA with or without
stenting) have been increasingly used as an alternative to
CE. However, whether endovascular treatments are more
effective than surgery in patients with carotid artery
stenosis remains unclear. This led to uncertainty over
the presence and magnitude of any protective effects of
endovascular treatments and surgery on stroke, and also
difficulties in interpretation of the results. Therefore, this
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systematic review and meta-analysis was conducted to
evaluate the possible effect of CE compared with CA on
stroke in patients with carotid artery stenosis.
Methods
Data sources, search strategy, and selection criteria
This review was conducted and reported according to
the Preferred Reporting Items for Systematic Reviews
and Meta-Analysis Statement [10] issued in 2009. Data
were gathered from randomized controlled trials to
evaluate the effect of CE compared with CA on the risk
of stroke. Trials comparing CE with CA were included,
excluding any studies with a sample size less than 50, to
alleviate systematic error and resulting bias, hence en-
suring the reliability of the conclusion.
The English literature was systematically searched to
identify all relevant randomized, controlled trials re-
gardless of publication status (published, in press, and
in progress). Relevant trials were identified using the
following procedures:
(1)Electronic searches: The PubMed, Embase, and the
Cochrane Central Register of Controlled Trials were
searched for randomized controlled trials of CE
compared with CA, using “endarterectomy,”,
“angioplasty,” “stenting,” stenosis,” “carotid,”
“human,” “English,”, and “randomized controlled
trials” as search terms. All reference lists from
reports on nonrandomized controlled trials were
searched manually for additional eligible studies.
(2)Other sources: Authors were contacted to obtain
any possible additional published or unpublished
data, and the site http://www.ClinicalTrials.gov was
searched for ongoing randomized controlled trials
that had been registered as completed but not yet
published, using the aforementioned terms. Medical
subject headings, methods, patient populations,
interventions, and outcome variables of these studies
were used to identify relevant trials.
The literature search, data extraction, and quality as-
sessment were undertaken independently by two authors
(CZ and FLC) using a standardized approach, and any
discrepancy was settled by group discussion. Studies
were eligible for inclusion if: (1) the study was a ran-
domized controlled trial; (2) sample size was more than
50; (3) the number of events for stroke that occurred
during the study was more than 10; (4) the trials
assessed the effects of CE compared with CA; and (5)
patients had carotid artery stenosis.
Data collection and quality assessment
All data from eligible trials were independently abstracted
in duplicate by two independent investigators (CZ and
FLC) using the standard protocol, and reviewed by a third
investigator (AJH). Any discrepancy was resolved by group
discussion. Data were extracted from the included trials
were as follows: name of first author or study group, publi-
cation year, number of patients, percentage of males, mean
age, history of disease, intervention, control, duration of
follow-up, and primary outcome (the number of incident
cases for each treatment group). One author (AJH) en-
tered the data into computer, and the primary author
(YHZ) checked it. The study quality was assessed using
the Jadad score [11], which was based on the following five
subscales: randomization (1 or 0), concealment of the
treatment allocation (1 or 0), blinding (1 or 0), complete-
ness of follow-up (1 or 0), and the use of intention-to-
treat analysis (1 or 0). A “score system” (ranging from 0 to
5) was developed for assessment. In this meta-analysis, a
study with a score of 4 or more was considered to be of
high quality.
Statistical analysis
The results of each randomized controlled trial was
compiled as dichotomous frequency data. Individual
study relative risks (RRs) and 95 % confidence intervals
(CIs) were calculated from event numbers extracted
from each trial before data pooling. The overall RR and
95 % CIs of stroke incidence, major vascular events,
myocardial infarction, and any possible adverse events
were also calculated. Both fixed-effects and random-
effects models were used to assess the pooled RR for CE
compared with CA. Although both models yielded simi-
lar findings, the results from the random-effects model
assumed that the underlying effect varied among in-
cluded trials [12, 13]. The heterogeneity of the treatment
effects between studies was investigated visually using
scatter plot analysis as well as statistically using the het-
erogeneity I2 statistic [14, 15]. A sensitivity analysis was
also performed by removing each individual trial from
the meta-analysis. An Egger’s test [16] was used to check
for potential publication bias. All the reported P values
were two-sided, and a P value less than 0.05 was
regarded as statistically significant for all included stud-
ies. All analyses were calculated using software STATA
(version 10.0).
Results
Of the 19 trials retrieved for detailed assessment, 10
were excluded because: they lacked data on stroke, they
reported on the same study population, [17] they were
of small sample size, or it was a stopped trial. The final
analysis included nine randomized controlled trials [18–26]
consisting of 7163 patients with carotid artery stenosis
(Fig. 1). These trials compared CE with CA, with stroke
reported as one of the endpoints. Table 1 summarizes the
characteristics of these trials and the important baseline
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information of the included 7163 patients. Of the nine
trials, two were performed in the USA [18, 20], four in
European countries [19, 21, 22, 24], one [23] in Germany,
Austria, and Switzerland, one [25] in the USA and
Canada, and one [26] in Europe, Australia, and Canada.
The number of patients ranged from 87 to 2502. The per-
centage of previous cases with cardiovascular disease
ranged from 11.9 to 80.7 %. The duration of follow-up
ranged from 0.3 to 5.4 years. The inclusion criteria were
restricted to randomized controlled trials with the number
of patients more than 50 to ensure that high-quality litera-
ture was included in the study. Although the included tri-
als scarcely reported on the key indicators of trial quality,
the quality of the included trials was also evaluated ac-
cording to the predefined criteria using the Jadad score
[11]. Overall, five [20–23, 25] of the included trials scored
4, two trials [19, 26] scored 3, and the remaining two trials
[18, 24] scored 2.
Data on the effect of CE on 30-day major vascular
events were available from 7 trials, which included 6911
patients and reported 424 major vascular events. Figure 2
shows the effect of CE on 30-day major vascular events
compared with CA. The pooled RR showed a 22 % re-
duction in 30-day major vascular events, but with no
evidence showing that CE protected against the risk of
vascular events (RR, 0.78; 95 % CI: 0.57–1.06; P = 0.11).
Some evidence of heterogeneity across the studies in-
cluded was available. A sensitivity analysis indicated that
CE was associated with a reduction in the risk of 30-day
major vascular events, which was decreased by 28 %
(RR, 0.72; 95 % CI: 0.54–0.94; P = 0.02, Fig. 2) when ex-
cluding SAPPHIRE trials [18]. This trial specifically
added an embolic protection device to carotid artery
stenting, which was more efficient in preventing major
vascular events. Similarly, no evidence was found to
show that CE protected against 1-year/within 1-year major
vascular events (RR, 0.69; 95 % CI: 0.40–1.18; P = 0.18,
Fig. 2). Substantial heterogeneity was observed in the
magnitude of the effect across the trials included, ac-
cording to a sensitivity analysis. It was concluded that
CE was associated with a reduction in the risk of 1-year/
within 1-year major vascular events, which was decreased
by 44 % (RR, 0.56; 95 % CI: 0.42–0.75; P < 0.001, Fig. 2)
when excluding SAPPHIRE trials [27]. Finally, the pooled
analysis showed no significant differences in the influence
of CE and CA on long-term (more than 1-year) major
vascular events (RR, 1.00; 95 % CI: 0.87–1.14; P = 0.95,
Fig. 2).
Fig. 1 Flow diagram of the literature search and trials selection process
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Data on the effect of CE on 30-day stroke were avail-
able from 6 trials, including 6692 patients and 330
events of stroke. Overall, CE resulted in a 35 % reduc-
tion in the risk of 30-day stroke compared with CA
(RR, 0.65; 95 % CI: 0.47–0.89; P = 0.007, Fig. 3). Des-
pite some evidence of heterogeneity across the studies
included, a sensitivity analysis indicated that the re-
sults were not affected by sequential exclusion of any
particular trial from the pooled analysis. Furthermore,
although CE reduced the risk of 1-year/within 1-year
stroke by 36 %, it was not associated with a statistically
significant difference (RR, 0.64; 95 % CI: 0.39–1.04;
P = 0.07, Fig. 3). A sensitivity analysis indicated that CE
was associated with a reduction in the risk of 1-year/
within 1-year stroke, which was decreased by 48 % (RR,
0.52; 95 % CI: 0.35–0.76; P = 0.001, Fig. 3) when excluding
SAPPHIRE trials [27]. Finally, when patients received CE,
the risk of long-term stroke was significantly reduced by
22 % compared with CA (RR, 0.78; 95 % CI: 0.66–0.93;
P = 0.006, Fig. 3).
Data for the effect of CE on 30-day mortality were
available from 6 trials, which included 6692 patients and
reported 59 events of death. No effect of CE on the risk
of 30-day mortality was observed (RR, 0.70; 95 % CI:
Fig. 2 Effect of carotid endarterectomy on the risk of major vascular events compared with carotid angioplasty
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0.41–1.21; P = 0.20, without evidence of heterogeneity,
Fig. 4). Similarly, no evidence was found to show that
CE could reduce the risk of 1-year/within 1-year mortality
(RR, 0.82; 95 % CI: 0.18–3.81; P = 0.80, Fig. 4) and long-
term mortality (RR, 0.98; 95 % CI: 0.85–1.13; P = 0.78,
without evidence of heterogeneity, Fig. 4).
The effect of CE on the risk of 30-day myocardial in-
farction was reported in 5 trials, which included 5509
patients and recorded 70 events of myocardial infarction.
Overall, it was noted that CE increased the risk of 30-
day myocardial infarction by 114 % compared with CA
(RR, 2.14; 95 % CI: 1.30–3.53; P = 0.003; Fig. 5). Only
three trials provided data on 1-year/within 1-year myo-
cardial infarction. It was noted that CE increased the risk
of 1-year/within 1-year myocardial infarction by 104 %,
but it was not associated with a statistically significant
difference (RR, 2.04; 95 % CI: 0.90–4.61; P = 0.09, Fig. 5).
Furthermore, only SAPPHIRE trials [27] provided data
on long-term myocardial infarction. No effect of CE on
the risk of long-term myocardial infarction events was
observed (RR, 1.56; 95 % CI: 0.69–3.49; P = 0.28).
Egger test [16] was used to check for potential publi-
cation bias, which showed no evidence of publication
bias for the outcomes of 30-day major vascular events
Fig. 3 Effect of carotid endarterectomy on the risk of stroke compared with carotid angioplasty
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(P value for Egger test, 0.889), 30-day stroke (P value
for Egger test, 0.902), and 30-day myocardial infarction
(P value for Egger test, 0.376). However, evidence was
found of publication bias for 30-day mortality (P value
for Egger test, 0.025). The conclusions were not chan-
ged after adjustment for publication bias using the
trim-and-fill method [28].
Discussion
A direct relationship was observed between the degree
of carotid artery stenosis and the risk of stroke. Although
CE has been considered the gold standard for the treat-
ment of carotid stenosis for decades, evidence from large-
scale randomized controlled trials [6] has shown that CA
has emerged as an alternative therapy for this common
disorder. The results of this meta-analysis showed that CE
reduced the risk of 30-day stroke and long-term stroke.
However, it also significantly increased the risk of myocar-
dial infarction compared with CA. Furthermore, sensitivity
analyses suggested that CE might influence the risk of 30-
day and 1-year/within 1-year major vascular events.
According to the SAPPHIRE trials [18, 27], the study
suggested that CA was not inferior to CE in preventing
the risk of stroke, whether short term or long term. The
present results were inconsistent with large-scale ran-
domized, controlled trials, probably because this trial
specifically added an embolic protection device to ca-
rotid artery stenting, which might have contributed
more efficacy in preventing the risk of stroke. Further-
more, EVA-3S trials [21, 29] indicated that in patients
with symptomatic carotid stenosis of 60 % or more, the
rates of death and stroke at 1 and 6 months were lower
with CE than with CA. SPACE trials [23, 30] failed to
prove the noninferiority of CA compared with CE in
terms of the periprocedural complication rate. Further-
more, it suggested a similar effect on the risk of ipsilateral
ischemic strokes between CE and CA. The present study
defined that benefits could be achieved when patients with
Fig. 4 Effect of carotid endarterectomy on the risk of mortality compared with carotid angioplasty
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carotid artery stenosis underwent CE. However, it was
also noted that CE significantly increased the risk of
short-term myocardial infarction. The risk of 1-year/
within 1-year myocardial infarction and long-term myo-
cardial infarction was not observed, probably because less
number of trial provided data for this result.
CE might play an important role in mortality, although
a significant difference was not observed. The reason for
this could be that CE also significantly increased the risk
of myocardial infarction, translating into an increased
risk of life-threatening events. CAVATAS trial [26, 31]
indicated that more patients had stroke during long-term
follow-up in the endovascular group than in the surgical
group. However, the rate of ipsilateral non-perioperative
stroke was low in both the groups, with no differences in
the stroke outcome measures. This conclusion was in ac-
cordance with the findings of the present meta-analysis.
This study was promising because randomized controlled
trials were restricted to meet the inclusion criteria, and
the aim was to provide the best evidence for a causal
relationship.
A previous meta-analysis [32] illustrated that carotid
artery stenting was inferior to CE with regard to the in-
cidence of stroke or death for periprocedural outcomes,
especially in symptomatic patients. Furthermore, it also
suggested that carotid artery stenting was associated with
a lower incidence of myocardial infarction. The present
study also confirmed that patients who underwent CE had
a high risk of myocardial infarction. However, it also indi-
cated that CE was associated with a statistically significant
reduction in the risk in stroke.
The major limitation of this study was the inherent as-
sumptions made for the meta-analysis. The analysis used
pooled data, whether from published papers or provided
by individual authors. Individual patient data and ori-
ginal data were not available, which restricted perform-
ing more detailed relevant analysis and obtaining more
comprehensive results. Additionally, no sufficient data were
available on detailed effects of CE on the risk of different
types of stroke. Furthermore, during the planning stages,
the intention was to perform subgroup analyses on the
basis of other confounders, which might affect the treat-
ment effect. However, the results of subgroup analyses on
the basis of follow-up duration might be unreliable because
of smaller cohorts included. This study attempted to
provide a comprehensive review on the comparison be-
tween the efficacy of CE and CA.
Conclusions
In conclusion, CE could reduce the risk of stroke (whether
short term or long term), and might influence the risk of
major vascular events compared with CA. However, it also
increased the risk of 30-day myocardial infarction. The
present study might guide appropriate judgments about
treatment approach. It also provided evidence to justify
general guidelines for patients with carotid artery stenosis.
Fig. 5 Effect of carotid endarterectomy on the risk of myocardial infarction compared with carotid angioplasty
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It is suggested that the following factors be improved in
future research: (1) the adverse effect events of clinical tri-
als should be recorded and reported normatively and (2)
myocardial infarction events should be taken into consid-
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